ArticleJournal of ovarian research2025
Ovarian reserve and stimulation response before chemotherapy treatment in breast cancer patients undergoing fertility preservation: a historical cohort study.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFertility preservation is an important aspect of care for breast cancer patients. This study was designed to compare the ovarian function including ovarian reserve and ovarian stimulation response in breast cancer patients undergoing controlled ovarian stimulation (COS) for fertility preservation before chemotherapy, and oocyte donors as healthy women.
methodsThis historical cohort study enrolled 78 breast cancer patients who underwent COS for fertility preservation between April 2014 and March 2022 at the Infertility Center of Royan Institute, Tehran, Iran. Sixty-six healthy oocyte donors were included as a control group during the same time period. The inclusion criteria were female patients aged ≤ 35 years, with confirmed breast cancer with indication of chemotherapy, who were elected for ovarian stimulation before chemotherapy for oocyte retrieval. Women with the diagnosis of poor ovarian response, polycystic ovary syndrome, severe male factor infertility, endometriosis, and those who used oral contraceptives excluded from the study. Main outcome measure was retrieved total number of mature oocytes.
resultsThe mean age was significantly higher and mean body mass index was significantly lower in the breast cancer group than in the oocyte donor group. There were also significant differences between groups in terms of hormonal profiles of luteinizing hormone and anti-mullerian hormone (AMH), gonadotropin starting dose, total dose of gonadotropin used and oocyte maturation rate. Based on the results, there was a significant correlation between Metaphase II and AMH in breast cancer group (r = 626; P < 0.001).
conclusionIt appears that patients with cancer experience diminished ovarian reserve prior to cancer treatment. Further prospective studies with larger sample sizes are recommended. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.